MPH

Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines

Retrieved on: 
Thursday, March 28, 2024
Health, Organization, TASK, Doctor of Philosophy, Assistant, Caregiver, Parent, Pharmacy, Comcast, Adolescence, Vaccine hesitancy, Social media, Research, Internet, MD, Trust, Immunization, MPH, TelevisaUnivision, Clinton Foundation, Vaccine, PSA, Vaccination

AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.

Key Points: 
  • AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.
  • Across the nation, organizations interested in the health of adolescents are participating in AIAW to help protect adolescents from vaccine-preventable illnesses.
  • To address these challenges, Unity wants parents to help adolescents and young adults stay healthy by Staying on TASK with vaccines.
  • As AIAW kicks off, Unity offers activities and resources to support Adolescent Immunization Action Week efforts, including:
    A graphic and video animation of Staying on TASK.

Tevogen Bio Announces Series A-1 Preferred Stock Investment

Retrieved on: 
Thursday, March 28, 2024
Neurology, Virology, MPH, Therapy, Medicine, Security (finance)

WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.

Key Points: 
  • WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has entered into a securities purchase agreement with an existing investor pursuant to which the investor agreed to purchase shares of newly designated Series A-1 Preferred Stock of the Company in lieu of Series A Preferred Stock that the investor earlier agreed to purchase, for an aggregate purchase price of $6.0 million.
  • The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.00 conversion price of the Series A Preferred Stock, into a total of 600,000 shares of the Company’s common stock at the election of the holder.
  • The Series A-1 Preferred Stock is subject to a call right providing the Company the right to call the stock if the volume weighted average price of the common stock for the 20 days prior to delivery of the call notice is greater than $5.00 per share and there is an effective resale registration statement on file covering the underlying common stock.
  • The Series A-1 Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year, with a cap of 12% per year.

Alira Health Joins Forces with APMA to Advance Podiatric Registry

Retrieved on: 
Wednesday, March 27, 2024
Real-World Evidence, Partnership, RWE, Health, Patient, Research, Foot, Ankle, American Podiatric Medical Association, Surgeon, CAE, MPH, APMA, DPM, Physician, Pharmaceutical industry

Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.

Key Points: 
  • Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.
  • The APMA registry supports researchers’ understanding of diseases and ways to treat them.
  • "APMA is excited by the opportunity to drive powerful research to improve patient care in conjunction with Alira Health," said APMA Senior Medical Director Dyane E. Tower, DPM, MPH, MS, CAE.
  • “Our partnership with APMA marks an advancement in accelerating innovation and new solutions for patients,” said Gabriele Brambilla, CEO of Alira Health.

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
Wednesday, March 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

Retrieved on: 
Wednesday, March 27, 2024
DYN, Therapy, MPH

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points: 
  • WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m.
  • ET.
  • A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

Treatment.com AI Funded by the National Institute of Health to Develop a Culturally Sensitive AI Approach to Health Equity

Retrieved on: 
Wednesday, March 27, 2024
Health, African Americans, Risk, Family, Historical trauma, AI, NIH, Treatment, OTC, MPH, FAAFP, FRCS, Artificial intelligence, Medical device

Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families.

Key Points: 
  • Treatment has partnered with Rush River Research in Minneapolis to develop an Artificial Intelligence (AI) approach for collecting information about family medical history that is culturally sensitive and appropriate for African-American families.
  • The historical trauma and systemic bias common in African American communities can limit the amount of information known about the health of relatives.
  • Without better methods for capturing information, existing health disparities addressing prevention and risk can persist.
  • The Company held multiple focus groups with African American doctors and community members to help develop and prototype culturally sensitive approaches to collecting information about family health.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
Tuesday, March 26, 2024
OCT, Optical coherence tomography, Patent, Multiple sclerosis, Capsule, Tablet, Code, MD, SPRINT, MPH, Tokyo Stock Exchange, Pharmaceutical industry

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

OOFOS Surpasses $4 Million Milestone in Project Pink Donations

Retrieved on: 
Tuesday, April 9, 2024
Ali, Breast cancer, Dana–Farber Cancer Institute, Patient, Research, Pink, Boston Marathon, The Jimmy Fund, Shoe, Woman, Microsoft Kin, MPH, PMC, Division, Nursing, Christine St-Pierre, Pharmaceutical industry

BRAINTREE, Mass., April 9, 2024 /PRNewswire/ -- OOFOS, the global leader in Active Recovery footwear, today proudly announces a monumental achievement in their Project Pink initiative, surpassing the extraordinary milestone of $4 million in all-time donations to Dana-Farber Cancer Institute and the Jimmy Fund. Through several fundraising initiatives, OOFOS solidifies its unwavering dedication to breast cancer awareness, research, and patient support.

Key Points: 
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Through Project Pink, OOFOS donates a portion of all sales made on OOFOS.com to Dana-Farber, ultimately leading to the $4 million.
  • In addition to ongoing contributions through Project Pink, OOFOS has undertaken various impactful campaigns to further contribute to this vital cause.